Graft-versus-host disease: why have we not made more progress?

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (allo-SCT) offers curative potential for hematologic malignancies but is limited by graft-versus-host disease (GVHD).
• GVHD affects approximately 50% of allo-SCT recipients and can be fatal.
• Current prevention strategies for GVHD have seen little advancement in two decades.

Purpose of the Study:

• To review the current understanding of GVHD pathogenesis.
• To evaluate the efficacy of existing and emerging GVHD treatments.
• To highlight challenges in clinical trial design for GVHD.

Main Methods:

• Review of recent literature on GVHD pathogenesis, prevention, and treatment.
• Analysis of clinical trial designs and their limitations.
• Discussion of advances in GVHD grading and biomarkers.

Main Results:

• The pathogenesis of acute and chronic GVHD is not fully understood.
• Corticosteroid treatment for GVHD shows suboptimal response rates.
• Steroid-refractory GVHD has dismal outcomes with second-line treatments.
• Clinical studies for new GVHD agents are inconsistent and lack multicenter validation.

Conclusions:

• Recent advances include improved grading systems for acute and chronic GVHD.
• Biomarkers show promise for prognostic information in acute GVHD.
• Standardized, prospective, multicenter studies are crucial for future GVHD prevention advancements.